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Cerebrospinal fluid VILIP-1 and YKL-40,
candidate biomarkers to diagnose, predict
and monitor Alzheimer’s disease in a
memory clinic cohort
Maartje I. Kester1*, Charlotte E. Teunissen2, Courtney Sutphen3,4,5, Elizabeth M. Herries6, Jack H. Ladenson6,
Chengjie Xiong3,7, Philip Scheltens1, Wiesje M. van der Flier1,8, John C. Morris3,4,5, David M. Holtzman3,4,5
and Anne M. Fagan3,4,5
Abstract
Introduction: We examined the utility of cerebrospinal fluid (CSF) proteins, Chitinase-3-like protein 1 (CHI3L1 or YKL-40),
a putative marker of inflammation, and Visinin-like protein-1 (VILIP-1), a marker for neuronal injury, for diagnostic
classification and monitoring of disease progression in a memory clinic cohort.
Methods: CSF levels of YKL-40 and VILIP-1 were measured in 37 cognitively normal, 61 Mild Cognitive Impairment (MCI)
and 65 Alzheimer’s disease (AD) patients from the memory clinic-based Amsterdam Dementia Cohort who underwent
two lumbar punctures, with minimum interval of 6 months and a mean(SE) interval of 2.0(0.1) years. Mean(SE) cognitive
follow-up was 3.8 (0.2) years. ANOVA was used to compare baseline differences of log-transformed CSF measures. Cox
proportional hazard models were used to evaluate disease progression as a function of CSF tertiles. Linear mixed models
were used to evaluate longitudinal change over time. All analyses were sex and age adjusted.
Results: Baseline levels of YKL-40, but not VILIP-1, were higher in MCI and AD patients compared to cognitively normal
individuals (mean (SE) pg/mL, 304 (16) and 288 (12) vs. 231 (16), p = 0.03 and p = 0.006). Baseline levels of both YKL-40
and VILIP-1 in MCI predicted progression to AD (HR 95 % CI = 3.0 (1.1–7.9) and 4.4 (1.5–13.0), respectively, for highest vs.
lowest tertile). YKL-40 increased longitudinally in patients with MCI and AD (mean (SE) pg/mL per year, 8.9 (3.0) and 7.1
(3.1), respectively), but not in cognitively normal individuals, whereas levels of VILIP-1 increased only in MCI (mean (SE),
10.7 (2.6) pg/mL per year).
Conclusions: CSF levels of YKL-40 may have utility for discriminating between cognitively normal individuals and patients
with MCI or AD. Increased levels of both YKL-40 and VILIP-1 may be associated with disease progression. These CSF
biomarkers should be considered for future evaluation in the characterization of the natural history of AD.
Introduction
Major efforts are underway to develop therapeutic strategies
to slow the progression of Alzheimer’s disease (AD). To
evaluate the effect of these interventions, biological markers
are needed that reflect progression of AD pathology. Cere-
brospinal fluid (CSF) biomarkers amyloid beta 1–42 (Aβ42),
total tau (tau), and tau phosphorylated at threonine 181
(ptau-181) reflect the neuropathology of AD and are useful
as diagnostic markers for AD [5]. In addition, these “classical
CSF biomarkers” predict progression to AD in cognitively
normal individuals and individuals with mild cognitive im-
pairment (MCI) [16, 18, 23, 47]. Several studies have evalu-
ated whether these classical CSF biomarkers could also be
used as markers to monitor progression of AD pathology in
affected individuals but, to date, their levels have not been
shown to be optimal markers for (therapeutic) monitoring
in longitudinal studies owing to their relative stability in the
later clinical stages of AD [6, 10, 14, 22, 33, 44, 48].
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We hypothesized that biomarkers of neuroinflammation
and neurodegeneration could be useful for monitoring dis-
ease progression in clinical AD, since amyloid plaque de-
position and tau tangle formation are early pathologic
processes, while neuroinflammation and neurodegeneration
may mark events downstream of Aβ and tau pathology
[20]. Two relatively novel biomarkers, Chitinase-3-like pro-
tein 1 (YKL-40; a secreted 40 kDa glycoprotein, also known
as CHI3L1) and Visinin-like protein-1 (VILIP-1), have re-
cently been shown to have additional diagnostic and prog-
nostic value in distinguishing individuals with symptomatic
AD from controls [3, 4, 15, 27, 35, 42, 43]. As an astrocyte-
derived and/or microglia-derived protein, YKL-40 has been
suggested to be associated with neuroinflammation, a process
also hypothesized as a major contributor to cognitive decline
in AD [7, 8, 15, 30]. VILIP-1 is a neuronal calcium-sensor
protein that has previously been reported to be increased in
the central nervous system CSF following stroke [12, 24, 40],
and thus is considered a marker of neuronal injury.
We aimed to evaluate the performance of these CSF bio-
markers for diagnostic and prognostic purposes in AD, and
additionally to assess their longitudinal value for the moni-
toring of disease progression. To achieve this, we evaluated
a memory clinic cohort of AD and MCI patients and cogni-
tively normal subjects who had available repeat CSF sam-
ples collected over time.
Methods
Patients
The cohort was comprised of memory clinic patients from
the Amsterdam Dementia Cohort diagnosed with AD
(n = 65) or MCI (n = 61) and those deemed cognitively
normal (n = 37) who had CSF collected at two time points
[22]. At baseline all patients underwent CSF collection and
standard dementia screening, including physical and neuro-
logical examination, laboratory tests, electroencephal-
ography, and magnetic resonance imaging. Cognitive
screening included a Mini-Mental State Examination
(MMSE; range 0–30, with 30 indicative of perfect per-
formance), but usually also involved comprehensive neuro-
psychological testing. The diagnosis of probable AD was
made according to National Institute of Neurological and
Communicative Disorders and Stroke–Alzheimer’s Disease
and Related Disorders Association criteria [32]. The diag-
nosis of MCI was made according to Petersen criteria [37],
and participants met the core clinical criteria for MCI
of the National Institute on Aging–Alzheimer’s Associ-
ation [2]. When the results of all examinations were nor-
mal, patients were considered to have subjective memory
complaints. The cognitively normal group consisted of 31
individuals with subjective memory complaints, two patients
with a psychiatric disorder, two patients with temporal epi-
lepsy, and two healthy volunteers. Diagnoses were made by
consensus of a multidisciplinary team without regard to
CSF biomarker results. The study was approved by the
ethical review board of the VU University Medical Center,
and all individuals gave written informed consent.
Follow-up
Patients were followed-up at the Amsterdam clinic.
Within the MCI group (follow-up mean (standard error
(SE)) 2.7 (0.3) years; range 0.1–10.9 years) 17 patients
remained stable, and 36 progressed to symptomatic AD
[32] and eight to other dementias (two to fronto-temporal
lobar degeneration [34], three to vascular dementia [39],
one to dementia with Lewy bodies, one to progressive
supranuclear palsy [31], and one diagnosed with normal
pressure hydrocephalus). Within the 37 cognitively normal
individuals (follow-up mean (SE) 4.0 (0.5) years; range 0.9–
9.6 years; n = 33), six patients with subjective complaints
progressed to MCI, three patients to AD, and one patient to
vascular dementia, while 27 patients remained stable. Dur-
ing follow-up, patients were asked to undergo a second
lumbar puncture (minimum interval 6 months; range 0.7–
6.2 years, with a mean of 2.0 years). At baseline, VILIP-1
data were unavailable for two patients and YKL-40 data for
one patient; at follow-up, VILIP-1 data were unavailable for
one patient and YKL-40 data for three patients. We used
all 679 available MMSE measurements to estimate annual
cognitive decline over time (MMSE at follow-up was avail-
able in 31 cognitively normal individuals, 59 MCI patients,
and 58 AD patients; mean (SE) 3.8 (0.2) years).
CSF analyses
CSF was obtained by lumbar puncture using a 25-gauge
needle and collected in 10 ml polypropylene tubes. Within
2 h, CSF samples were centrifuged at 1800 × g for 10 min at
4 °C. CSF was aliquoted in polypropylene tubes of 0.5 or
1 ml and stored at −80 °C until further analysis. Baseline
CSF Aβ42, tau, and ptau-181 were measured with INNOT-
EST ELISA (Fujirebio Europe (formerly Innogenetics),
Gent, Belgium) at the VU University Medical Center,
Amsterdam [9]. The inter-assay coefficient of variation
(%CV) (mean ± standard deviation) was 10.9 ± 1.8 % for
Aβ42, 9.9 ± 2.1 % for tau, and 9.1 ± 1.8 % for ptau-181,
as analyzed in a high pool and a low pool from 13 con-
secutive pool preparations used in total in 189–231
runs. At Washington University in St. Louis, CSF sam-
ples were analyzed for YKL-40 by enzyme-linked im-
munosorbent assay (ELISA; Quidel, San Diego, CA, USA)
and for VILIP-1 by a microparticle-based immunoassay
(Erenna; Singulex, Alameda CA, USA) [15, 42]. Intra-
assay and inter-assay %CV values were 4.4 % and 10.6 %
for YKL-40, and were 3.1 % and 8.6 % for VILIP-1, re-
spectively. To circumvent inter-assay variability, baseline
and follow-up samples were analyzed on the same assay
plate [11, 46].
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Statistical analysis
Cross-sectional differences among diagnostic categories
were assessed using analysis of variance (ANOVA), ad-
justed for sex and age, with post-hoc Bonferroni cor-
rections, or the Fisher exact test when applicable. For
ANOVA, CSF biomarkers were log-transformed to fit
the assumptions needed for the model. For subgroup
analyses with ANOVA, the MCI group was divided
into stable MCI patients and MCI patients progressing
to symptomatic AD, and analyses were performed in
the same manner. Cox proportional hazard models
adjusting for sex and age were performed to analyze
the predictive value of CSF biomarkers for progression
of MCI to AD, and then for progression of MCI to all
types of dementia. For the Cox analyses we used the CSF
biomarkers in tertiles (YKL-40: lowest tertile, <219 ng/ml;
middle tertile, 219–328 ng/ml; highest tertile, > 328 ng/ml;
VILIP-1: lowest tertile, <131 pg/ml; middle tertile, 131–
200 pg/ml; highest tertile, >200 pg/ml). For all analyses, the
lowest tertile was used as the reference. The same analyses
were also performed using CSF biomarkers as continuous
variables. Hazard ratios (HRs) are presented with a 95 %
confidence interval (CI). Kaplan–Meier curves were made
for illustrative purposes. In addition, we estimated the effect
of baseline levels of YKL-40 and VILIP-1 on cognitive de-
cline as defined by repeated MMSE. For this purpose, we
used linear mixed models with the baseline CSF biomarker
level (YKL-40 or VILIP-1) in tertiles (as already described),
time (years), and interaction between time and CSF
biomarker as independent variables, and the MMSE
score as the dependent variable. We adjusted for age
and sex, and analyses were performed separately for
each diagnostic category. All available MMSE scores
were taken into account, and all mixed models were
specified with a random intercept and/or slope based
on –2 Log Likelihood criteria [45]. Finally, age and sex-
adjusted linear mixed models were applied to assess
within-person annual changes over time in CSF biomarker
levels in each of the diagnostic groups. The CSF bio-
markers (YKL-40 and VILIP-1) were the dependent vari-
ables (each in a separate model), while diagnosis (treated
as a categorical variable), time (in years; treated as a con-
tinuous variable), and interaction between diagnosis and
time were independent variables. Diagnostic categories
were recoded as dummy variables to be able to estimate
the mean (SE) for each category. For statistical analyses,
IBM SPSS 21 (for Windows; Armonk, New York, USA)
was used. Statistical significance was set at p ≤0.05.
Results
Baseline characteristics
MCI patients were older than those who were cognitively
normal, as shown in Table 1. MMSE scores were lower in
both symptomatic AD and MCI individuals compared with
cognitively normal individuals, and lower in AD compared
with MCI. APOE ε4 carriership was more common in AD
than in cognitively normal individuals. CSF Aβ42 levels
were, as expected, lower in both AD and MCI groups
compared with those who were cognitively normal, and
lower in AD compared with MCI. CSF tau and ptau-
181 levels were higher in both AD and MCI groups
compared with those who were cognitively normal.
Levels of CSF biomarkers at baseline as a function of clinical
diagnosis
Mean baseline YKL-40 levels were different among the
three diagnostic groups (p = 0.006). Pair-wise comparisons
with Bonferroni corrections showed that baseline YKL-40
levels were higher in MCI and AD patients, compared with
the cognitively normal individuals (mean (SE) 304 (16) and
288 (12) ng/ml vs. 231 (16) ng/ml, p = 0.03 and p = 0.006),
as shown in Table 2. Although mean baseline levels of
VILIP-1 in MCI and AD patients were higher than those in
cognitively normal individuals (mean (SE), 192 (13) and
182 (10) pg/ml vs. 168 (11) pg/ml), the differences were not
statistically significant (effect for diagnosis p = 0.88).
Predictive value of baseline levels of biomarkers for
progression of MCI to symptomatic AD
Further analyses with ANOVA showed that baseline
levels of YKL-40 were higher in MCI patients who
Table 1 Patient baseline characteristics and CSF biomarkers in
diagnostic groups
Cognitively normal MCI AD
(n = 37) (n = 61) (n = 65)
Age (years) 64 (2) 68 (1)* 65 (1)
Sex, female 14 (38 %) 23 (38 %) 29 (45 %)
MMSE at baseline
(range 0–30)a
28 (0.3) 27 (0.3)* 22 (0.7)†,‡
APOE genotype, ε4 carrierb 15 (42 %) 33 (57 %) 45 (70 %)*
Follow-up time (years) 2.4 (0.2) 2.0 (0.1) 1.9 (0.1)
CSF biomarkers
Aβ42 (pg/ml) 741 (44) 530 (32)† 412 (18)†,‡
tau (pg/ml) 349 (38) 606 (64)† 688 (44)†
ptau-181 (pg/ml) 54 (4) 78 (6)† 86 (4)†
Data presented as mean (standard error) or number (percentage). Fisher’s exact test
or ANOVA with post-hoc Bonferroni corrections were used when applicable. CSF
biomarkers were log-transformed for ANOVA analyses
aBaseline MMSE (with 30 indicative of perfect performance) was available for
160 patients, and follow-up MMSE was available for 148 patients; the cognitive
follow-up period was (mean (standard error) 3.8 (0.2) years)
bAPOE genotype data were available for 36 cognitively normal individuals, 58
MCI patients, and 64 AD patients (total 158)
*p ≤ 0.05 vs. cognitively normal
†p ≤ 0.005 vs. cognitively normal
‡p ≤ 0.005 vs. MCI
Aβ42 amyloid beta 1–42, AD Alzheimer’s disease, ANOVA analysis of variance,
CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini-Mental
State Examination, ptau-181 tau phosphorylated at threonine 181, tau total tau
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progressed to AD (n = 36) compared with stable MCI
patients (n = 17, mean (SE), 327 (19) ng/ml vs. 242 (31)
ng/ml, p = 0.01), as shown in Table 3. Baseline levels of
YKL-40 were also predictive of progression from MCI to
AD, with HR (95 % CI) of 3.0 (1.1–7.9) for the highest
tertile and 2.9 (1.0–8.1) for the middle tertile of YKL-40,
compared with the reference (lowest tertile), as shown in
Fig. 1.
Similar to the results observed for YKL-40, ANOVA ana-
lyses showed that baseline levels of VILIP-1 were higher in
MCI patients that progressed to AD (n = 35) compared
with stable MCI patients (n = 17) (mean (SE) 233 (17)
pg/ml vs. 136 (25) pg/ml, p = 0.001, respectively). Base-
line levels of VILIP-1 in individuals with MCI were pre-
dictive of progression to AD, with HR (95 % CI) of 4.4
(1.5–13.0) for the highest tertile and 2.1 (0.7–6.7) for
the middle tertile, compared with the reference (lowest
tertile).
When repeating these analyses with CSF biomarkers as
continuous variables, effects remained the same (HR (95 %
CI): YKL-40 1.003 (1.001–1.006), p = 0.02; VILIP-1 1.005
(1.002–1.008), p = 0.003). In addition, results were virtually
identical when analyzing for progression of MCI to all
types of dementia (n = 44) instead of progression to AD
alone (HR (95 % CI): YKL-40 3.2 (1.3–7.9) for the high-
est tertile and 2.9 (1.1–7.2) for the middle tertile; VILIP-1
3.8 (1.5–9.4) for the highest tertile and 1.7 (0.6–4.4) for the
middle tertile).
Predictive value of baseline levels of biomarkers for
cognitive decline as measured by MMSE
Baseline levels of YKL-40 were predictive for cognitive
decline in AD (β (SE) 0.65 (0.29), p = 0.03), but not in those
who were cognitively normal or had MCI (β (SE) –0.10
(0.13), p = 0.44 and −0.32 (0.19), p = 0.11, respectively).
Cognitive decline for those AD patients in the lowest
tertile of YKL-40 was 2.8 MMSE points per year, while
patients with levels in the highest tertile decreased 1.5
points annually. Baseline levels of VILIP-1 were predict-
ive of cognitive decline as measured by MMSE in MCI (β
(SE) –0.39 (0.19), p = 0.05), but not in cognitively normal or
AD patients (β (SE) 0.01 (0.15), p = 0.95 and 0.13 (0.27),
p = 0.64, respectively). Cognitive decline in MCI with
VILIP-1 levels in the lowest tertile was 0.7 MMSE points
per year, while patients with levels in the highest tertile de-
clined 1.5 MMSE annually.
Longitudinal changes of biomarkers
Mixed model analyses showed that levels of YKL-40 within
individuals increased in both MCI and AD patients (mean
Table 2 Baseline levels of CSF biomarkers and change within
individuals over time
Cognitively normal MCI AD
(n = 37) (n = 61) (n = 65)
YKL-40 (ng/ml), baseline 231 (16) 304 (16)* 288 (12)*
YKL-40 (ng/ml), follow-up 241 (18) 320 (16)* 306 (14)†
Annual change, (β (SE)) 5.3 (3.2) 8.9 (3.0)‡ 7.1 (3.1)§
VILIP-1 (pg/ml), baseline 168 (11) 192 (13) 182 (10)
VILIP-1 (pg/ml), follow-up 175 (11) 217 (14) 190 (11)
Annual change, (β (SE)) 2.8 (2.8) 10.7 (2.6)‡ 3.1 (2.6)
Data presented as mean (SE). At baseline, VILIP-1 data were missing for two
patients and YKL-40 data for one patient; at follow-up, VILIP-1 data were
missing for one patient and YKL-40 data for three patients. Baseline and
follow-up differences (mean (SE) LP interval was 2.0 (0.1) years) were
assessed with ANOVA with post-hoc Bonferroni corrections, adjusted for age
and sex. CSF biomarkers were log-transformed for ANOVA analyses. Longitudinal
effects were assessed using age and sex-adjusted linear mixed models, with CSF
biomarkers (VILIP-1 and YKL-40) as dependent variables and clinical diagnosis
(categorical), time (LP interval in years), and interaction diagnosis × time as
independent variables. The reported β value represents the estimated
change of YKL-40 (ng/ml) or VILIP-1 (pg/ml) levels per year
*p ≤0.05 vs. cognitively normal subjects
†p ≤0.005 vs. cognitively normal subjects
‡p ≤0.005 for time effect
§p ≤0.05 for time effect
AD Alzheimer’s disease, ANOVA analysis of variance, CSF cerebrospinal fluid,
LP lumbar puncture, MCI mild cognitive impairment, SE standard error,
VILIP-1 Visinin-like protein-1, YKL-40 Chitinase-3-like protein 1
Table 3 Baseline characteristics and CSF biomarkers in mild
cognitive impairment
sMCI MCI-AD
(n = 17) (n = 36)
Age (years) 64 (2) 70 (1)*
Sex, female 6 (35 %) 13 (36 %)
MMSE (range 0–30)a 28 (0.6) 26 (0.4)*
Aβ42 579 (493–814) 410 (322–507)**
tau 274 (212–418) 739 (463–950)**
ptau-181 47 (40–79) 90 (65–124)**
YKL-40 (ng/ml), baseline 242 (31) 327 (19)*
YKL-40 (ng/ml), follow-up 247 (23) 363 (22)*
Annual change, (β(SE)) 10.2 (6.4) 10.1 (3.1)‡
VILIP-1 (pg/ml), baseline 136 (25) 233 (17) **
VILIP-1 (pg/ml), follow-up 167 (20) 256 (19)**
Annual change, (β(SE)) 16.4 (6.1)§ 12.0 (3.0)‡
Data presented as mean (SE) or number (percentage). At baseline VILIP-1 data
were missing for two patients and YKL-40 for one patient. Fisher’s exact test or
ANOVA with post-hoc Bonferroni corrections was used when applicable. CSF
biomarkers were log-transformed for ANOVA analyses. Longitudinal effects
were assessed using age and sex-adjusted linear mixed models, with CSF
biomarkers (VILIP-1 and YKL-40) as dependent variables and clinical diagnosis
(sMCI vs. MCI-AD), time (LP interval in years), and interaction diagnosis × time
as independent variables. The reported β value represents the estimated
change of YKL-40 (ng/ml) or VILIP-1 (pg/ml) levels per year
aBaseline MMSE was available for 52 patients
*p ≤0.05 vs. sMCI
**p ≤0.005 vs. sMCI
‡p ≤0.005 for time effect
§p ≤0.05 for time effect
Aβ42 amyloid beta 1–42, ANOVA analysis of variance, CSF cerebrospinal fluid,
LP lumbar puncture, MCI-AD mild cognitive impairment progressing to Alzheimer’s
disease, MMSE Mini-Mental State Examination, ptau-181 tau phosphorylated at
threonine 181, sMCI stable mild cognitive impairment, SE standard error, tau total
tau, VILIP-1 Visinin-like protein-1, YKL-40 Chitinase-3-like protein 1
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(SE) 8.9 (3.0) ng/ml per year, p = 0.004 and 7.1(3.1) ng/ml
per year, p = 0.02, respectively), but not in the cognitively
normal group (p = 0.10), as shown in Table 2 and Fig. 2.
Levels of VILIP-1 increased over time in MCI patients
by mean (SE) 10.7 (2.6) pg/ml per year (p <0.001), but
levels did not change significantly in cognitively normal
Fig. 1 Kaplan–Meier curve for progression of MCI to AD. Progression of MCI to AD for tertiles of YKL-40 (upper) and VILIP-1 (lower). For YKL-40:
lowest tertile, <219 ng/ml (light gray line); middle tertile, 219–328 ng/ml (dark gray line); and highest tertile, >328 ng/ml (black line). For VILIP-1:
lowest tertile, <131 pg/ml (light gray line); middle tertile, 131–200 pg/ml (dark gray line); and highest tertile, >200 pg/ml (black line). Lowest tertile
used as reference. AD Alzheimer’s disease, VILIP-1 Visinin-like protein-1, YKL-40 Chitinase-3-like protein 1
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individuals or AD patients (p = 0.31 and p = 0.23,
respectively).
Discussion
Baseline levels of both YKL-40 and VILIP-1 in CSF were
higher in MCI patients who progressed to AD, compared
with those who were clinically stable, and higher levels of
both biomarkers predicted progression from MCI to
symptomatic AD. Results for progression to all types of
dementia (including but not limited to AD) were essen-
tially the same, suggesting that these biomarkers reflect
pathologies that are not specific for AD (e.g., inflamma-
tion and/or neurodegeneration). In addition, we confirm
that levels of YKL-40 were higher in MCI and AD patients
compared with cognitively normal individuals. Further-
more, we show that levels of YKL-40 increased over time
in both MCI and AD, and that levels of VILIP-1 increased
over time in MCI, indicating that both of these CSF bio-
markers might be useful for disease monitoring.
The finding of higher levels of YKL-40 in MCI and
AD compared with cognitively normal individuals is
consistent with previous studies in CSF and brain [3, 4,
15, 26, 30, 35]. Our results also show that higher YKL-
40 levels were predictive for development of subsequent
cognitive impairment in MCI, a finding that is consistent
with data from a large group of cognitively normal indi-
viduals in an independent cohort [15], but differs
slightly from results of another study [35]. Within indi-
viduals with AD dementia, lower levels of YKL-40 were as-
sociated with a more rapid cognitive decline than were
higher levels, which seems counterintuitive. Further
studies evaluating a more complex set of cognitive tests
will allow for a testing of the validity and implications
of these results.
Fig. 2 Annual increase of CSF levels of YKL-40 and VILIP-1. Annual changes of CSF biomarker levels were assessed using age and sex-adjusted linear mixed
models, with CSF biomarkers (VILIP-1 and YKL-40) as dependent variables and clinical diagnosis (categorical), time (LP interval in years), and
interaction diagnosis × time as independent variables. The reported β value represents the estimated change of YKL-40 (ng/ml) or VILIP-1 (pg/ml) levels
per year. Error bars represent SE of the reported effect. *p ≤0.005 for time effect, †p ≤0.05 for time effect. AD Alzheimer’s disease, MCI mild
cognitive impairment, VILIP-1 Visinin-like protein-1, YKL-40 Chitinase-3-like protein 1
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We found that YKL-40 levels increased longitudinally
during the stages of MCI and AD, but not in cognitively
normal individuals, which implies that the increment
over time reflects clinical (symptomatic) disease progres-
sion. Although the role of YKL-40 in AD has not been
completely elucidated, the protein appears to be expressed
in astrocytes and/or microglia, with expression associated
with reactive gliosis and neuroinflammation [7, 8, 15, 30].
Levels of YKL-40 in CSF are also increased following
stroke, and in other neurological disorders, indicating
that it is not specific for AD but instead seems to be a
more general marker for inflammation [8, 19, 28, 29].
Our finding of increases in YKL-40 over time in both
MCI and AD is consistent with the fact that inflamma-
tion is a key process in disease progression in AD [1]
and as such could be a useful marker for monitoring dis-
ease progression.
Levels of VILIP-1 increased over time in patients with
MCI, but not in those with AD dementia. VILIP-1 is a
brain-specific neuronal calcium-sensor protein which may
play a role in signal transduction and neurotransmission
[12, 24]. It also has been associated with increased hyper-
phosphorylation of tau in the brain, and neuronal cell
death [13, 40]. Our results suggest that the pathological
processes associated with increased levels of VILIP-1,
such as neuronal dysfunction and death, are mainly ac-
tive in an earlier phase of the disease. This pattern is consist-
ent with findings in individuals carrying AD-causing gene
mutations [17]. In cross-sectional analyses, the present re-
sults showed higher levels of VILIP-1 in individuals with
MCI and AD compared with cognitively normal individuals;
however, this difference did not reach statistical significance
in contrast to prior publications [17, 25, 27, 42, 43]. Of note,
the absolute levels of VILIP-1 in the present study were
roughly twofold lower than those reported in the previous
studies that used the same assay, probably owing to the re-
cent improvement in assay calibration. However, the relative
differences between the clinical groups were the same in
both sets of studies. The lack of statistical difference
could reflect the relatively small number of cognitively
normal subjects evaluated (n = 37), the fact that a fair
number of controls progressed to some having MCI or
dementia over 4 years (n = 10), and differences between
the demographic and clinical characteristics of the control
groups between sets of studies. The cognitively normal
group in the current study was biased towards patients
who showed decline (six patients progressed to MCI
and four patients to dementia), and the percentage of
APOE ε4 carriership in our cognitively normal group was
higher than reported in the previous studies (i.e., 42 % vs.
17–29 %) [27, 43], and higher than in the general popula-
tion (20–25 %) [38], suggesting a potentially higher
prevalence of preclinical AD in this population. Such
differences could have diluted the diagnosis effect. The lack
of difference between our “control” and AD groups should
be interpreted with caution. In our cohort we also observed
a high rate of progression to AD in the MCI group. This
observation may reflect a selection bias in that progressors
may be more likely to return to our clinic for a second
lumbar puncture. Despite these differences and limita-
tions, we confirm that higher VILIP-1 levels are associ-
ated with progression of MCI to AD and more rapid
cognitive decline in MCI [42, 43]. Furthermore, in this
longitudinal cohort we were able evaluate biomarker
change over time as a “biological marker” for disease
progression. It will be of interest to evaluate the utility
of this marker in memory clinic settings for predicting pro-
gression of cognitively normal individuals to MCI once we
obtain a larger number of individuals and years of clinical
follow-up. Ideally, evaluation of longitudinal changes in
CSF YKL-40 and VILIP-1 will be performed in a cohort of
individuals as they progress from being cognitively normal
to having mild cognitive impairments and eventually AD
dementia. This would permit the characterization of the
true changes in these markers with disease progression.
Conclusions
We studied two relatively novel CSF biomarkers for AD in
a group of memory clinic patients, both cross-sectionally
and longitudinally. Both YKL-40 and VILIP-1 were associ-
ated with clinical disease progression. VILIP-1 seems of
most value in earlier stages (i.e., MCI), and could be a
marker of neuronal injury and early decline, reaching a
plateau earlier than YKL-40. In the setting of previously
proposed models, our data suggest that YKL-40 CSF levels
begin to increase before the stage of MCI and keep increas-
ing during the symptomatic stages of AD in contrast to the
more classic CSF biomarkers that reach a plateau [21, 36,
41]. Results from in vitro and animal studies suggest that
YKL-40 is a nonspecific biomarker for inflammation which
is a key process in AD disease progression [20]. YKL-40
could thus be especially valuable in monitoring and pre-
dicting disease progression within the phase of clinical
(symptomatic) AD, possibly also in the setting of future
modifying therapies in AD, especially those that would
target inflammatory processes.
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